Tracers / [213Bi]Bi-DOTA-TOC
[213Bi]Bi-DOTA-TOC
Also written as DOTATOC; DOTA-TOC
- Radionuclide
- Bi-213 t½ 45.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 0
What it is
- Compound class
- —
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/ga68-dotatoc/">ga68-dotatoc</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [213Bi]Bi-DOTA-TOC, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Stage 26: this agent has NO own synthesis/characterisation data in the current corpus -- its only linked run(s) were unlinked (empty-quote recheck: appeared only as a control/comparator or in the wrong article).